Idogen’s CEO Anders Karlsson leaves for a new assignment and Christina Herder is appointed acting CEO

Idogen's CEO Anders Karlsson leaves for a new assignment and Christina Herder is appointed acting CEO

Idogen AB (publ) declared that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company. He will remain in his current position until 1 September 2022; the board is now starting a process to recruit a successor. Christina Herder, who has been a board member of the company for more than five years, has been appointed acting CEO while the recruitment of a new CEO is underway. She will retain her role on the board during this time.

Anders Karlsson, resigning CEO of Idogen says “It has been a privilege to lead Idogen for the past three years and I am convinced that the company’s competent board and employees will continue to deliver significant progress for the benefit of large patient groups as well as the shareholders,”.

Christina Herder, incoming CEO of Idogen says“I am looking forward to being operationally involved in the advancement of the IDO 8 program in these exciting times, as we soon will be starting our Phase I/IIa study in the Nordic region,”.

Idogen develops tolerogenic cell therapies with the potential to restore the tolerance of the immune system in order to counteract its attacks against biological drugs, transplanted organs or the body’s own tissue. The company’s most advanced project IDO 8 aims to treat hemophilia patients who have developed an incorrect immune response to their drug treatment. Idogen has received approval from the Swedish and Norwegian pharmaceutical authorities to start a first clinical phase I/IIa study with IDO 8 in patients with hemophilia.

Leave a Reply

Your email address will not be published. Required fields are marked *